Abstract This study was designed to evaluate the prevalence of cardiometabolic comorbidities and the changes in left ventricular geometry and function in 135 subjects subgrouped according to low or normal total adiponectin plasma (ADPN) levels. Left ventricular (LV) internal diameter/height, total LV mass (LVM) and LVM index (LVMI), relative wall thickness (RWT), LV ejection fraction by echocardiography and diastolic parameters by pulsed-wave Doppler were calculated. Body mass index (BMI) (p \ 0.0001), waist-to-hip ratio (p \ 0.03), triglycerides (p \ 0,001), prevalence of obesity (p \ 0.005), visceral obesity (p \ 0.003), left ventricular hypertrophy (LVH) (p \ 0.001), metabolic syndrome (p \ 0.0003) and coronary artery disease (CAD) (p \ 0.003) were significantly increased and high-density lipoprotein-cholesterol (p \ 0.001) was significantly reduced in hypo-ADPN than normal-ADPN subjects. LVM, LVMI, interventricular septum thickness and RWT were significantly (p \ 0.0001) higher and left ventricular ejection fraction was significantly (p \ 0.0002) lower in hypo-ADPN than normal-ADPN patients. LVMI correlated directly with BMI (p \ 0.001), mean blood pressure (p \ 0.001), metabolic syndrome (MetS) (p \ 0.001) and inversely with ADPN (p \ 0.0001). The prevalence of LVH (p \ 0.001) and CAD (p \ 0.01) was higher in subjects with normal-ADPN and MetS, while the presence of MetS did not change this finding in hypo ADPN group. Both models of regression analysis indicated that ADPN and BMI resulted independently associated with LVMI. In conclusion, our data seem to indicate that hypoadiponectinemia might be associated with an increased prevalence both of clinical comorbidities and increased LVMI. In this subset of subjects, ADPN and BMI, more than MetS, are able to explain cardiac damage. Accordingly, ADPN might become a new target in the management of cardiometabolic risk.
Introduction
Recent studies have demonstrated the critical role of adipose tissue as an endocrine organ that, by secretion of adipocytokines, can affect several processes leading to the development of cardiometabolic disease [1] [2] [3] .
Adiponectin (ADPN), a collagen-like protein, is the most abundant circulating protein secreted by adipocytes. It is recognized as a key regulator of insulin resistance, tissue inflammation, and other pathophysiological processes [1, 3, 4] . It has been demonstrated that ADPN has several antiatherogenic and antidiabetic properties. A growing body of evidence suggests that a decrease in ADPN plasma levels plays an important part in the pathogenesis of many comorbid conditions, such as hypertension, diabetes, metabolic syndrome and atherosclerosis [1] [2] [3] [4] [5] [6] .
Accordingly, experimental and clinical studies indicate that low levels of ADPN are associated with endothelial dysfunction, higher risk of myocardial infarction, carotid atherosclerosis and with vulnerability of coronary plaque [1, 2, 4, [7] [8] [9] . In addition our previous data [10] and some clinical studies report an inverse association between ADPN and left ventricular mass (LVM) and diastolic dysfunction [11] [12] [13] . On the other hand, increased ADPN expression can attenuate LVH induced by pathological stimuli. ADPN may directly inhibit hypertrophic signaling in the myocardium by activating adenosine monophosphate-activated kinase, which activates eukaryotic elongation factor-2 kinase and the inhibitor of cardiac myocyte protein synthesis. ADPN protects the ischemic heart from injury through the activation of independent pathways that involve both adenosine monophosphate-activated kinasemediated antiapoptotic actions and cyclooxygenase-2-mediated antiinflammatory actions [14] [15] [16] .
Despite these data, the role of ADPN on cardiometabolic disease has been previously studied only in patients with preexisting diseases, such as type 2 diabetes, hypertension and obesity. We want instead to analyze the prevalence of cardiometabolic comorbidities and the changes in LVM in patients subgrouped according to normal or low ADPN. The main goal of the study was to evaluate whether hypoadiponectinemia might be considered a suitable cardiometablic biomarker.
Subjects and methods

Subjects
Subjects eligible for the study were screened at the center of hypertension and metabolic disease at the Department of Internal Medicine, University of Palermo (Italy). The study population consisted of 135 consecutive subjects. Each patient gave a written consent after receiving a detailed description of the study procedure. The study was approved by the Ethics Committee of our institution. For all participants, the clinic examination included interviews, anthropometry, blood pressure (BP) measurements, resting electrocardiogram, Doppler echocardiography and a fasting collection of blood for determination of biochemical parameters and plasma ADPN. Information regarding medical history, drug use, and alcohol and cigarette consumption was collected during a face-to-face interview using a standardized questionnaire. We enrolled only untreated or patients on stable treatment in order to have the best possible ''real'' correspondence between obtained clinical measurements (BP, glycemia, etc.), LVM and pharmacological treatment. We have chosen this methodology, since the approach based on discontinued 2 weeks before enrollment led to a return of clinical measurements toward original levels without a similar regression in LVM. This is an important confounding factor that we think is often overlooked. Subjects with psychiatric problems or alcoholism were excluded.
Height was measured on a clinic stadiometer, body weight was measured by electrical bioimpedance, using a body composition analyzer model TB-300 (Tanita, Tokyo, Japan) and body mass index (BMI) was calculated. Waist circumference was measured by plastic tape as the narrowest circumference between the lower rib margin and anterior superior iliac crest. Brachial BP was measured three times during three different visits, with a standard sphygmomanometer after 5 min of rest. The mean value was used in statistical analysis.
In all the subjects recruited, the following cardiometablic comorbidities were evaluated:
1. Obesity and visceral obesity: The subjects were defined as obese on the basis of gender-specific 85th percentile of BMI values, as reported in the Italian Consensus Conference on Obesity [17] . Accordingly, the men with BMI higher than or equal to 30 kg/m 2 and the women with BMI higher than or equal to 27.3 kg/m 2 were considered obese. On the contrary, the men with BMI less than or equal to 25 kg/m 2 and the women with BMI less than or equal to 24.7 kg/m 2 were considered lean. Visceral fat distribution was defined on the basis of gender-specific 85th percentile of waist-to-hip ratio (WHR). The cut-off values of visceral obesity were 0.81 for women and 0.92 for men [18] 
Methods
Biochemical measurements
Blood samples were collected in the morning after at least 8 h of fasting. Serum glucose, creatinine and clearance, glycemia, electrolytes, total cholesterol, triglycerides and high density lipoprotein-cholesterol (HDL-C) were measured using an ADVIA1650 Automatic Analyzer (Siemens, New York, USA). An immunoradiometric assay with an insulin RIA kit (Biosource, Belgium) was used to measure serum insulin. The HOMA index was calculated as fasting plasma glucose concentration (mmol/l) multiplied by fasting plasma insulin concentration (pmol) and divided by 22.5, and it was used as an index of IR. IR was defined as an HOMA-IR in the highest quintile of its distribution [23] . The concentration of total ADPN was obtained by a radioimmunoassay using a human ADPN RIA kit (LINCO Research, Inc., Billerica, MA, USA). In a previous analysis, ADPN levels had excellent intraclass correlation coefficient measured in participants over a period of 1 year and were not substantially affected by transport conditions [24] .
All subjects were grouped according to the following level of ADPN: higher than or equal to 6 lg/ml (normal ADPN group) and \6 lg/ml (hypo ADPN group). According to standard criteria of laboratory analysis, the cut-off value of ADPN (6 lg/ml) was related to the mean value ± double standard deviation of young healthy control sample (without a family history of premature cardiovascular disease) from our laboratory. Our ADPN cutoff values are in agreement with those reported by others [24, 25] .
Normal ADPN group: Patients with normal ADPN value (C6 lg/ml) consisted of 95 subjects (53 men and 42 women), with a mean ADPN level of 9.1 ± 2 lg/ml and a mean age of 51.3 ± 9.8 years ( Table 1) .
Hypo ADPN group: Patients with lower ADPN value (\6 lg/ml) consisted of 40 subjects (21 men and 19 women) with a mean ADPN level of 5.1 ± 0.7 lg/ml and a mean age of 48.2 ± 6.6 years ( Table 1) .
Echocardiographic measurements
All patients underwent an echocardiography examination M and B-mode, by a computerized echocardiography (ESAOTE, Italy) for the determination of following parameters: left ventricular internal diameter/height (LVID/h), and interventricular septum thickness (IVST), The Penn convention was used to calculate LVM. LVM was normalized for height to the 2.7 power (LVMI) [21, 26] . We chose to investigate LVH as defined by LVM/h 2.7 cut-offs because body surface area correction reduces variability due to body size and gender [26] and underestimates LVM in the upper range of the body surface area distribution [27] .
The relative wall thickness (RWT) by formula [(PWTd/ LVIDd) 9 2] was also calculated. Left ventricular ejection fraction (LVEF), diastolic and systolic volumes were measured from the apical four chamber view, using the ellipsoidal single-plane algorithm. Mean LVEF was automatically calculated by the echocardiographic processing system. In our laboratory LVEF calculated over five consecutive beats permitted optimal reproducibility and accuracy [26] .
Left ventricular (LV) relaxation and filling were evaluated by pulsed-wave Doppler interrogation of the LV inflow tract from the apical four-chamber view, with the sample volume placed at the tips of the mitral valve. After a stable signal of the transmitral flow velocity was obtained, the Doppler cursor was moved toward the LV outflow tract in the apical five-chamber view for recording Isovolumic relaxation time (IVRT) was calculated as the time from the closure click of the aortic valve to the opening click of the mitral valve. When either the closing or opening click was not identified, the time from the end of the aortic flow to the onset of mitral flow from the continuos wave interrogation of the LV inflow-outflow tract was used. Peak early transmitral flow velocity (E), peak late transmitral flow velocity (A), and the deceleration time of E velocity (DTE) were measured at the tips of mitral leaflets at the maximum amplitude of E velocity. DTE was measured as the time from peak E velocity to the time when E wave descent intercept the zero line.
Statistical analysis
Data are shown as mean ± SD. The Chi-square and the Fisher exact test were used for contingency table analysis. The Mann-Whitney U test was used for comparison between groups. Z test was used for comparison between two proportions. Linear regression analysis was performed to study relationship among independent variables and LVMI. Multiple fractional polynomial analysis was performed to study the best power fit between each independent variable and the dependent one. We used two regression models to test the independent role of risk factors for LVMI. Age, gender, MetS and ADPN were included in the model 1, whereas age and some single components of MetS (BMI, MBP, diabetes) and ADPN were included in the model 2. A two tailed p value \0.05 was used as cut-off for statistical significance. STAT/SE, version 9.2 for Windows (StataCorp. College Station, TX, USA), was used to analyze the data.
Results
Baseline characteristics of the study population All the subjects were subdivided into the following two groups, according to ADPN plasma levels cutoff (6 lg/ml): normal ADPN and hypo-ADPN subjects.
The clinical characteristics of the study groups are shown in Table 1 . Both groups were comparable with regard to sex and age.
BMI (p \ 0.0001), WHR (p \ 0.03) and triglycerides (p \ 0,001) were significantly increased and HDL-C (p \ 0.001) was significantly reduced in hypo-ADPN than normal-ADPN subjects. ADPN levels were obviously significantly (p \ 0.0001) lower in hypo-ADPN than normal-ADPN subjects. All the remaining clinical parameters were not significantly different between groups (Table 1) .
Prevalence of comorbidities
Hypo-ADPN subjects were characterized by a significant higher prevalence of patients with obesity (p \ 0.005), visceral obesity (p \ 0.003), LVH (p \ 0.001), MetS (p \ 0.0003) and CAD (p \ 0.003) in comparison with , LVID/h left ventricular internal diameter/ height, IVST interventricular septal thickness, RWT relative wall thickness, LVEF left ventricular ejection fraction, E/A peak early transmitral flow/peak late transmitral flow, DTE E deceleration time, IVRT isovolumic relaxation time, n.s. not significant normal-ADPN patients. On the contrary, the prevalence of diabetes, hypertension and IR was not significantly different between groups (Table 2) .
Echocardiographic measurements LVM, LVMI, IVST and RWT values were significantly (p \ 0.0001) higher and LVEF values were significantly (p \ 0.0002) lower in hypo-ADPN subjects than those detectable in normal-ADPN patients. All the remaining echocardiographic parameters were not significantly different between the two groups (Table 3) .
In addition, LVMI values correlated directly with BMI (r = 0.34; p \ 0.001), MBP (r = 0.29; p \ 0.001), MetS (r = 0.28; p \ 0.001) and inversely with ADPN (r = -0.57; p \ 0.0001) ( Table 4) .
To explain the interaction between ADPN and MetS on the cardiac damage, the two groups of patients (with normal or low ADPN levels) were further subdivided into four subgroups, according to the concomitant presence or absence of MetS. An higher prevalence of LVH (p \ 0.001) and CAD (p \ 0.01) was found, but only in subjects with normal-ADPN and MetS respect to subjects with normal-ADPN without Mets. On the contrary, in subjects with hypo-ADPN the presence of MetS did not change the prevalence of LVH and CAD (Table 5) .
Multiple regression analysis
Regression models were used to test the independent role of risk factors for LVMI.
Both in model 1, including age, gender, MetS and ADPN, and in model 2, including age, ADPN and some single components of MetS (BMI, MBP, diabetes), ADPN resulted independently associated with LVMI. In model 2 BMI was also independently associated with LVMI (Table 6 , model 1 and model 2).
Discussion and conclusions
Low serum ADPN is common in subjects with obesity, hypertension or atherosclerotic disease. ADPN may prevent the development of metabolic and atherosclerotic disorders and hypoadiponectinemia is currently considered a predictor of future cardiovascular events [9, 10, 28] . ADPN also plays an important role in myocardial remodeling [14] [15] [16] 29] . Despite these data, some recent metaanalyses on the association between ADPN levels and risk of cardiovascular disease report a positive [30] , negative [31] or no statistically significant [32] association. All of these data originate from studies that have investigated the protective role of ADPN in patients with preexisting diseases (hypertension, type 2 diabetes, obesity). To our knowledge, our work is the first study reporting the prevalence of cardiometabolic comorbidities and the changes in left ventricular geometry in subjects subgrouped according to normal or low ADPN.
Our data indicate that patients with low ADPN were characterized by a significant higher prevalence of obesity, visceral obesity, LVH, MetS and CAD compared to patients with normal ADPN levels. Hypoadiponectinemia might be considered a suitable ''cardiometabolic biomarker''. This opinion might be further supported by the relevant role of ADPN on left ventricular geometry and function demonstrated by us. In fact, in our population LVMI correlated positively with BMI, MBP and MetS and negatively with ADPN. Multiple regression analysis indicated that LVMI-ADPN and LVMI-BMI relationships remained independent also when adjusted for MetS or for its components. The LVMI-ADPN relationship also remains independent of BMI. These results suggest that ADPN and BMI may be considered the best predictors of LVH rather than the metabolic syndrome, above all else in patients with low ADPN.
In view of this, it is necessary to emphasize that it has been previously demonstrated that MetS had a greater impact on LVH above all in females and its effect was partly independent of the effect of several determinants of LVM [33] . We found that the presence of MetS is able to influence the prevalence of LVH and the increased LVMI, but only in subjects with normal ADPN. On the contrary, this effect disappears in subjects with low ADPN. This finding is in agreement with some studies indicating that MetS is not able to predict LVH independent of increased adiposity. The strong independent LVMI-BMI relationship , BMI body mass index, WHR waist hip ratio, MBP mean blood pressure, ADPN total plasma adiponectin, HDL-C high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, MetS metabolic syndrome
found by us seems to support this hypothesis, and, although WHR, as a single component, was not an independent determinant of LVH in our analysis, there is increasing evidence that regional fat distribution may contribute to cardiac remodeling and hypertrophy [1, 10] . Therefore it is still unclear if the MetS, even across different definitions, adds something more than the sum of each of its components in predicting organ damage. In our study the MetS was not able to predict LVH independent of ADPN. When the different components of MetS were included in multiple regression models only ADPN and BMI had an independent relationship with LVMI. This finding indicates that ADPN and BMI have to be considered the most important factor, rather than the MetS, associated with changes in cardiac geometry in subjects with hypoadiponectinemia. In addition, the lack of abnormalities in diastolic function found by us might be explained by the age of the patients studied. For these reasons, the increased values of LVMI might be considered an early cardiac alteration in these subjects. Recently, the role of ADPN in relation to cardiac geometry and function has attracted some attention. Several studies performed in small study samples, mostly in patients with preexisting disease, such as type 2 diabetes, hypertension, or obesity, have reported inverse associations between adiponectin, LVM and diastolic dysfunction [11, 12, 23, 34] . Similarly, a larger sample of healthy Japanese men shows an association between lower levels of adiponectin and dichotomous electrocardiography-LVH as an outcome [13] . There are, however, very few large , LVID/h left ventricular internal diameter/height, IVST interventricular septal thickness, RWT relative wall thickness, LVEF left ventricular ejection fraction, E/A peak early transmitral flow/peak late transmitral flow, DTE E deceleration time, IVRT isovolumic relaxation time, pts patients, LVH left ventricular hypertrophy, CHD coronary heart disease * z test: z = 5.223; p \ 0.001 vs patients with normal ADPN and MetS ** z test: z = 3.207; p \ 0.01 vs patients with normal ADPN and MetS , MetS metabolic syndrome, ADPN total plasma adiponectin, BMI body mass index, WHR waist to hip ratio, MBP mean blood pressure community-based studies with adequate adjustment for potential confounders to elucidate these relations in greater detail; to our knowledge, only one prior study has investigated the relation of ADPN with LV geometry and function in a moderately large sample of healthy individuals [34] .
Nevertheless, other recent studies, performed on patients who are receiving dialysis or have diabetes and who are at a higher risk of LVH [23] than the general population, report a positive relationship between the ADPN and LVM. These two different relationships between adiponectin level and LVM indicate different mechanisms influencing ADPN production. In addition, experimental data indicate that ADPN decreases with LVH progression and than increases after systolic dysfunction develops [35] .
Another aspect is related to the pathophysiologic role of ADPN on LVH. The common belief is that the mechanisms able to increase LVM are not limited to haemodynamic changes. In fact, a large population-based study shows that only about 50 % of LVM variation can be explained by demographic and hemodynamic factors [36, 37] . Thus, non-hemodynamic mechanisms are likely to contribute to an increase in LVM and wall thickness. In this field an important role has recently been attributed to adipocytokines [1, 2, 10-12, 14, 15, 29] .
The negative relation between ADPN and LVMI by us found in subjects with high cardiometabolic risk may also contribute to this mechanism. A lack of protective effects of ADPN might cause an increase in LVM in these subjects. It has been shown that decreased plasma ADPN levels may lead to LVH by directly affecting LVM, and that an increase in ADPN levels may be effective in correcting the pathologic change in cardiac structure. Accordingly, ADPN administration might have a practical clinical application to restore LVH [38] .
As reported in ''Introduction'', several mechanisms have been suggested to explain the role of hypoadiponectinemia on the occurrence of LVH [14, 15] .
Another possible mechanism may be the suppression of angiotensin II-stimulated myocyte hypertrophy with ADPN [16] , but our study is not sufficient to explain these mechanisms because of its cross section design. However, the presence of a negative relationship between ADPN and LVMI in subjects with hypoadiponectinemia might suggest that decreased myocardial protein synthesis via the inhibition of hypertrophic signaling may play a more important role in explaining ADPN associated myocardial protection.
Some limitations of this study must be taken into account. First, our population is made exclusively of patients studied in the Centre of Hypertension and Metabolic Disease. This selection ''bias'' can explain the prevalence of MetS, diabetes, hypertension and dyslipidemia. Thus, our study is relevant for an important condition commonly found in ''real life'' medical practice. Second, we were not able to take into account all the details of all the different classes and subtypes of drugs consumed by the patients, which in turn might have affected the results obtained. However, this is a common limitation of many published works when ''real practice'' patients are studied. Third, it has been designed to be a cross-sectional study. Evaluation of the cause-effect relationship between hypoadiponectinemia and LVH would require a prospective study design with a cohort base and larger case statistics. Therefore, we cannot prove causality or predictive ability, but only discern association.
In conclusion, the present study indicates that hypoadiponectinemia was powerfully associated to a higher prevalence of clinical cardiometabolic comorbidities and to increased LVMI. In this particular subset of patients, characterized by the contemporaneous presence of cardiometabolic disorders and hypoadiponectinemia, ADPN and BMI, more than the MetS, are able to explain the development of cardiac damage. Clinical long-term follow-up with large number of participants is needed to validate this hypothesis, also evaluating whether the increase in ADPN levels induced by an appropriate therapy might be able to restore LVH. According to emerging data [39] , ADPN levels might become a new target in the management of cardiometabolic risk.
